Title |
Acute exacerbations in patients with idiopathic pulmonary fibrosis
|
---|---|
Published in |
Respiratory Research, August 2013
|
DOI | 10.1186/1465-9921-14-86 |
Pubmed ID | |
Authors |
Dong Soon Kim |
Abstract |
Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial lung disease that primarily affects older adults. Median survival after diagnosis is 2--3 years. The clinical course of IPF may include periods of acute deterioration in respiratory function, which are termed acute exacerbations of IPF (AEx-IPF) when a cause cannot be identified. AEx-IPF may represent a sudden acceleration of the underlying disease process of IPF, or a biologically distinct pathological process that is clinically undiagnosed. An AEx-IPF can occur at any time during the course of IPF and may be the presenting manifestation. The incidence of AEx-IPF is hard to establish due to variation in the methodology used to assess AEx-IPF in different studies, but AEx-IPF are believed to occur in between 5 and 10% of patients with IPF every year. Risk factors for AEx-IPF are unclear, but there is evidence that poorer lung function increases the risk of an AEx-IPF and reduces the chances of a patient surviving an AEx-IPF. The presence of comorbidities such as gastroesophageal reflux disease (GERD) and pulmonary hypertension may also increase the risk of an AEx-IPF. AEx-IPF are associated with high morbidity and mortality. Patients who experience an AEx-IPF show a worsened prognosis and AEx-IPF are believed to reflect disease progression in IPF. Current treatments for AEx-IPF have only limited data to support their effectiveness. The latest international treatment guidelines state that supportive care remains the mainstay of treatment for AEx-IPF, but also give a weak recommendation for the treatment of the majority of patients with AEx-IPF with corticosteroids. There is emerging evidence from clinical trials of investigational therapies that chronic treatment of IPF may reduce the incidence of AEx-IPF. Additional clinical trials investigating this are underway. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 2% |
Spain | 1 | 2% |
Netherlands | 1 | 2% |
Unknown | 50 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 11 | 21% |
Other | 7 | 13% |
Student > Postgraduate | 7 | 13% |
Student > Bachelor | 4 | 8% |
Researcher | 4 | 8% |
Other | 14 | 26% |
Unknown | 6 | 11% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 33 | 62% |
Agricultural and Biological Sciences | 5 | 9% |
Nursing and Health Professions | 2 | 4% |
Chemistry | 2 | 4% |
Economics, Econometrics and Finance | 2 | 4% |
Other | 2 | 4% |
Unknown | 7 | 13% |